Biosimilars: A marathon, not a sprint for pharma
by Bain partners Nils Behnke, Norbert Hueltenschmidt, Andy Pasternak and Karan Singh
While it is hard to predict exactly how—or when—the market for biosimilars will evolve, their potential impact on the global pharmaceuticals industry cannot be ignored. Just as generics emerged as a powerful force in the last two decades, for many in the pharma industry, biosimilars will be a strong agent for change in the future—either through disruption or innovation. ... '
Friday, May 21, 2010
Bain writes on Biosimilars, a term I have not heard for a while, though it came up in research work.